Abstract
111In Capromab Pendetide (ProstaScintR) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. It has proven to be of great value in assisting management decisions in prostate cancer patients who initially present with high risk for metastatic spread, or who develop a picture of recurrent disease after surgery or radiation therapy. Patterns of metastatic lymphatic spread have correlated well with autopsy reports in the literature. Unfortunately, other imaging study and/or histologic confirmation of scintigraphic findings has been difficult to obtain. Prostascint's role in predicting durable complete response (DCR) in postoperative patients having salvage radiotherapy to their prostate fossa is very promising. Further investigative work in larger patient populations is needed to confirm these early results.
Original language | English (US) |
---|---|
Pages (from-to) | 131-137 |
Number of pages | 7 |
Journal | Quarterly Journal of Nuclear Medicine |
Volume | 46 |
Issue number | 2 |
State | Published - Jun 2002 |
Keywords
- Antibodies, monoclonal
- Lymph nodes, radionuclide imaging
- Prostatic neoplasms, diagnosis
- Prostatic neoplasms, radionuclide imaging
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging